The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1643
February 7, 2022
View Complete Issue         Table of Contents 2019 
Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms
February 7, 2022 (Issue: 1643)
The FDA has approved adjunctive treatment with Dartisla ODT (Edenbridge), a new orally disintegrating tablet (ODT) formulation of the anticholinergic drug glycopyrrolate, to reduce symptoms of a peptic ulcer. Glycopyrrolate oral tablets (Robinul,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms
Article code: 1643e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.